Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 356.15B | 343.33B | 251.87B | 142.79B | 118.56B | 430.28B |
Gross Profit | 114.67B | 110.62B | 82.74B | 28.26B | 16.38B | 69.90B |
EBITDA | 23.04B | 22.37B | 11.95B | 6.95B | -36.42B | -18.32B |
Net Income | 9.65B | 8.72B | -2.62B | -9.55B | -50.05B | -25.04B |
Balance Sheet | ||||||
Total Assets | 396.43B | 412.20B | 441.35B | 414.98B | 411.45B | 414.60B |
Cash, Cash Equivalents and Short-Term Investments | 111.89B | 138.17B | 157.59B | 145.01B | 101.42B | 95.23B |
Total Debt | 185.78B | 211.86B | 266.15B | 276.75B | 277.36B | 248.56B |
Total Liabilities | 329.14B | 349.86B | 383.20B | 358.35B | 347.30B | 316.18B |
Stockholders Equity | 56.18B | 52.25B | 48.98B | 47.82B | 34.55B | 74.13B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | 21.05B | 24.59B | -23.83B | -44.96B | -124.28B |
Operating Cash Flow | 0.00 | 29.25B | 31.07B | -14.91B | -28.40B | -57.72B |
Investing Cash Flow | 0.00 | 45.61B | -46.39B | 53.52B | -7.09B | -47.90B |
Financing Cash Flow | 0.00 | -55.16B | -11.79B | 5.46B | 40.71B | -5.60B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | ¥180.19B | 9.95 | 15.56% | 3.28% | 5.69% | 48.81% | |
72 Outperform | ¥218.18B | 13.97 | 6.29% | 3.67% | 31.75% | -9.71% | |
68 Neutral | ¥337.27B | 27.73 | 15.31% | 0.57% | 23.05% | 31.52% | |
67 Neutral | ¥167.17B | 63.81 | 9.31% | ― | 68.78% | -45.75% | |
61 Neutral | ¥385.68B | 23.29 | 22.16% | 1.27% | 11.92% | 33.70% | |
54 Neutral | $106.40B | 16.26 | 13.31% | 0.69% | 14.32% | -4.49% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% |
H.I.S. Co., Ltd. announced disciplinary actions following an investigation that revealed its subsidiary, Tour Wave Co., Ltd., wrongfully received an Employment Adjustment Subsidy. Tour Wave has repaid the subsidies, and the president’s compensation has been reduced. The incident is expected to have an insignificant impact on H.I.S.’s financial results, though investigations are ongoing.
The most recent analyst rating on (JP:9603) stock is a Hold with a Yen1579.00 price target. To see the full list of analyst forecasts on H.I.S.Co. stock, see the JP:9603 Stock Forecast page.
H.I.S. Co., Ltd. has announced progress in implementing measures to prevent the recurrence of issues related to fraudulent receipt of employment adjustment subsidies. The company is focusing on fostering compliance awareness, strengthening group governance, reviewing internal controls for public subsidy applications, improving labor management, promoting the whistleblowing system, and enhancing the internal audit system. These steps aim to restore trust and improve operational efficiency, impacting the company’s industry positioning and stakeholder confidence.
The most recent analyst rating on (JP:9603) stock is a Hold with a Yen1579.00 price target. To see the full list of analyst forecasts on H.I.S.Co. stock, see the JP:9603 Stock Forecast page.
H.I.S. Co., Ltd. has reported extraordinary financial results for the first nine months of the fiscal year ending October 31, 2025, including both income and losses. The company recorded an extraordinary income of 1,366 million yen due to the reversal of allowance for doubtful accounts, attributed to improved earnings of its subsidiaries. Conversely, it also reported an extraordinary loss of 1,677 million yen due to the write-down of shares in its scaled-back subsidiary, HIS ULUSLARARASI TURIZM SEYAHAT ACENTASI LIMITED SIRKETI, impacting its non-consolidated financial results.
The most recent analyst rating on (JP:9603) stock is a Hold with a Yen1579.00 price target. To see the full list of analyst forecasts on H.I.S.Co. stock, see the JP:9603 Stock Forecast page.
H.I.S. Co., Ltd. has revised its full-year financial forecast for the fiscal year ending October 31, 2025, due to significant changes in its Turkish subsidiary’s operations. The subsidiary experienced increased outbound business volume but faced challenges from the declining Turkish lira and inflation, leading to a decision to scale back operations and record extraordinary losses. This adjustment has resulted in a downward revision of the company’s profit forecast, impacting its financial outlook.
The most recent analyst rating on (JP:9603) stock is a Hold with a Yen1579.00 price target. To see the full list of analyst forecasts on H.I.S.Co. stock, see the JP:9603 Stock Forecast page.
H.I.S. Co., Ltd reported consolidated financial results for the nine months ending July 31, 2025, showing a 12.2% increase in net sales compared to the previous year. However, profit attributable to owners of the parent decreased by 50.2%. The company revised its full-year financial forecast, anticipating a 13.6% increase in net sales and a 25.4% decrease in profit attributable to owners of the parent. The company also announced changes in its scope of consolidation, excluding six subsidiaries.
The most recent analyst rating on (JP:9603) stock is a Hold with a Yen1579.00 price target. To see the full list of analyst forecasts on H.I.S.Co. stock, see the JP:9603 Stock Forecast page.
H.I.S. Co., Ltd reported a 12.7% increase in net sales to 181,313 million yen for the six months ending April 30, 2025, with operating profit rising by 21.6% to 6,721 million yen. The company also announced a dividend of 10 yen per share for the fiscal year ending October 31, 2025, reflecting a positive outlook despite excluding three subsidiaries from consolidation.
The most recent analyst rating on (JP:9603) stock is a Hold with a Yen1580.00 price target. To see the full list of analyst forecasts on H.I.S.Co. stock, see the JP:9603 Stock Forecast page.